New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to receive brodalumab 210mg, brodalumab 140mg, ustekinumab, or placebo. They found that 37 percent of patients receiving a 210mg dosage of brodalumab achieved total clearance, as compared to 27 percent of patients taking 140mg brodalumab and 18.5 percent patients taking ustekinumab. Additionally, 85.1 percent of patients receiving brodalumab 210mg achieved PASI 75, as compared to 69.2 percent of patients on brodalumab 140mg, 69.3 percent of patients on ustekinumab, and six percent of patients receiving placebo. Serious adverse events were somewhat more common with brodalumab than with ustekinumab, but were still uncommon, according to the authors.